Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-04-09

Clinical Trial Update: TMC435-TiDP16-C112 - Interaction Trial With Antidepressants [Phase 1]

View source ↗

Summary

Phase 1 interaction trial evaluating telaprevir (TMC435) with antidepressants in hepatitis C patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Telaprevir (TMC435) (telaprevir)

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED